Market Research Report

Global Human Insulin Market Research Report: Forecast (2023-2028)

By Product Type (Human Insulin Drugs [Insulin Analogs & Biosimilars, Human Insulin Biologics], Human Insulin Delivery Devices [Syringes, Pens, Pen Needles]), By Application (Type I...Diabetes, Type II Diabetes), By Region (North America, South America, Europe, The Middle East & Africa, Asia-Pacific), By Company (B. Braun (B. Braun Melsungen), Becton, Dickinson and Company (BD), Biocon Limited, Biodel Inc., Eli Lilly and Company, Julphar (Gulf Pharmaceutical Industry), Novo Nordisk A/S, Sanofi, Wockhardt Ltd., The Ypsomed Group, Others) Read more

  • Healthcare
  • Mar 2023
  • 197
  • HC22110

Market Definition

Insulin is a pharmaceutical preparation of the protein hormone insulin produced by the human pancreas. It controls the amount of glucose (sugar) levels in the bloodstream, regulates the uptake of amino acids by body cells, and the metabolism of fats, proteins, and carbohydrates. Diabetes is a chronic medical condition in which the human body does not produce enough insulin or the cells stop responding to the it, leading to too much blood sugar in the bloodstream. This condition can cause health problems such as heart disease, vision loss, etc., and requires the administration of such harmone on a daily basis.

Market Insights & Analysis: Global Human Insulin Market (2023-28)

The Global Human Insulin Market is projected to grow at a CAGR of around 5.4% during the forecast period, i.e., 2023-28. The increasing number of diabetes cases globally favors market growth. In addition, the growing exposure of people to risk factors such as a sedentary lifestyle and obesity is increasing the chances of diseases and conditions like diabetes and high blood pressure. Thus, the rising prevalence of diabetes supports the adoption of human insulin as a treatment, fueling market expansion.

Technological advancements, research, and development in product variations and delivery methods have played a significant role in accelerating market growth. For instance, Afrezza (Mannkind) is the only inhaled form available, eliminating the need for needles and syringes. Fiasp (Novo Nordisk) is a formulation combined with Vitamin B3 (niacinamide) to improve initial absorption.

Report Coverage Details
Study Period Historical Data: 2018-21
Base Year: 2022
Forecast Period: 2023-28
CAGR (2023-2028) 5.4%
Regions Covered North America: US, Canada, Mexico
Europe: Germany, The UK, France, Spain, Italy, Rest of Europe
Asia-Pacific: China, India, Japan, South Korea, Australia, Rest of Asia-Pacific
South America: Brazil, Argentina, Rest of South America
Middle East & Africa: GCC, South Africa, Rest of MEA
Key Companies Profiled B. Braun (B. Braun Melsungen), Becton, Dickinson and Company (BD), Biocon Limited, Biodel Inc., Eli Lilly and Company, Julphar (Gulf Pharmaceutical Industry), Novo Nordisk A/S, Sanofi, Wockhardt Ltd., The Ypsomed Group, Others
Unit Denominations USD Million/Billion

 

Favorable reimbursement policies in developed countries support the adoption of human insulin. However, the lack of such policies in emerging nations and undiagnosed cases could hinder market expansion. Meanwhile, the shift of consumers to analogs and biosimilars from human insulin biologics is likely to garner the attention of the growing diabetes population, promising further industrial opportunities. For instance,

  • In July 2021, Semglee, an insulin product interchangeable with and biosimilar to Lantus made by India’s Biocon, got United States approval.

Global Human Insulin Market Research Report: Forecast (2023-2028)

Global Human Insulin Market Key Drivers:

Surging Prevalence of Diabetes and Increased Insulin Product Launches - Diabetes cases are dramatically rising due to obesity and a sedentary lifestyle. Additionally, diabetes now affects all age groups, expanding the need for treatment and care. Moreover, the significant number of new product launches and higher utilization of insulin is further pushing the market forward. Major participants are introducing numerous new products, and manufacturers focus on creating unique products, driving industrial growth. For instance,

  • In May 2022, Eli Lilly and Company got approved for their Mounjaro injection, which helps Type 2 diabetes patients improve their glycemic control.  

Global Human Insulin Market Possible Restraint:

Inadequate Health Reimbursement and Lower Diagnosis Rate in Emerging Countries - Though the awareness and demand for insulin have increased, resulting in adoption and advancements in new products, the lack of reimbursement in developing and emerging countries with under-developed healthcare sectors is likely to restrain the market growth. Additionally, the lack of reimbursement, leading to increased patient expenditure in financing out-of-pocket drugs, could threaten the adoption of products. Furthermore, the higher rate of undiagnosed cases and lower diagnosis rate of diabetes in emerging countries could hamper industrial expansion.

For instance, according to International Diabetes Federation, almost 1 in 2 (240 million) adults living with diabetes are undiagnosed, and 3 in 4 adults with diabetes live in low and middle-income countries. Since reimbursement encourages the adoption of treatment and diagnosis leads to treatment; thus, inadequate health reimbursement and lower diagnosis rate in developing countries are likely to hinder the industrial expansion.

Global Human Insulin Market Growth Opportunities

Rising Research and Development in The Treatment and Prevention of Diabetes - Rising cases of diabetes have become a health concern worldwide, which has concerned various diabetes preventative and other healthcare awareness organizations. Consequently, concerned countries and organizations have fueled scientists to progressively work towards the development of advanced and superior forms of insulin to boost effectiveness and reduce adverse effects. The market participants are actively investing in research to develop better combinations of drugs to overcome the challenges of daily multiple injections and further reduce hypoglycemia risk. For instance,

  • In November 2021, Biocon, in collaboration with the Research Society for the Study of Diabetes in India (RSSDI), launched a comprehensive care program for Type 1 diabetic patients.

 Thus the rising investment in the research and development of diabetes treatment and insulin variations, with increasing collaborations and partnerships amongst the business participants and medical centers, promises numerous growth opportunities for the market players.

Global Human Insulin Market Key Trends:

The Consumers’ Shift to Insulin Analogs - With the launch and introduction of insulin analogs, consumers and patients are now provided with replacement strategies for conventional products. The higher adherence of insulin analogs to therapy, increased efficiency, and response rate, in combination with a lower risk of hypoglycemia, have boosted its adoption. Furthermore, lesser side effects, such as lower weight gain combined with shorter absorption and impact time, have again fueled its demand. Thus, the more effective and practical options, resulting from improvements in research such as better composition and delivery techniques, have accelerated the consumer shift to analogs fueling industrial growth while raising product value. 

Global Human Insulin Market (2023-28): Segmentation Analysis

Global Human Insulin Market report by Markntel Advisors includes segmentation analysis based on Product Type and Applications. This breakdown allows businesses to identify specific market segments and tailor their marketing and product strategies accordingly, maximizing their chances of success in the Global Human Insulin Market.

Based on Product Type,

  • Human Insulin Drugs
    • Insulin Analogs & Biosimilars
      • Long Acting Biosimilars
      • Rapid Acting Biosimilars
      • Premixed Biosimilars
    • Human Insulin Biologics
  • Human Insulin Delivery Devices
    • Syringes
    • Pens
    • Pen Needles

Among them, Insulin Analogs and Biosimilars dominated the global market in the historical period and are expected to continue in the same trend in the forecast years. The growth is attributed to the higher demand for biologics, which have shifted consumer preference, leading to further industry expansion. Further, the low maintenance and ease of installation and handling of monoplane HBOT devices are boosting the adoption of premixed biosimilars, coupled with user-friendly operability and adherence to therapy and glycemic control of analogs, combined with the reduced risk of hypoglycemia compared to conventional biologics.

Besides, analogs' increased efficacy and response rate and minimal adverse effects, such as lower weight gain than traditional options, are propelling industrial growth. Along similar lines, analogs tend to clump less, absorb more predictably, and act in a shorter time than human insulin, leading to extended market acceleration.

Based on Application

  • Type I Diabetes
  • Type II Diabetes

Amongst the two, Type I Diabetes is expected to acquire a larger market share in the coming years, aided by the surging prevalence of diabetes and the daily application and requirement of injections to control blood glucose levels in Type I Diabetes. In Type I Diabetes, the pancreas does not produce such hormone due to the immune system attacking the islet cells in the pancreas responsible for its production.

In contrast, in Type II Diabetes, the pancreas makes less insulin than required, and the body may become resistant to it. Therefore, among the two, Type I diabetes is dependent on insulin and requires it for treatment, thus leading to industrial acceleration in the segment.

Contrarily, the market is expected to expand at a slower rate in Type II Diabetes, given the varieties of other treatment options available for patients and since insulin is prescribed to Type II diabetes patients only when the different treatment options become refractory. On the other hand, the increasing risk of developing Type II diabetes globally foreshadows a steady growth in the future.

Global Human Insulin Market Regional Projection

Geographically, the Global Human Insulin Market expands across:

  • North America
  • South America
  • Europe
  • Middle East & Africa
  • Asia-Pacific

Globally, North America dominated the industry during the historical period and is anticipated to acquire the largest market share during the forecasting period, following the same trend. The predominant growth of the region is attributed to the constantly increasing prevalence of diabetes due to the sedentary lifestyle. Moreover, the presence of major participants and fierce competition amongst the business in response to growing cases of Type 1 diabetes adds to the industrial expansion.

Additionally, the increasing cost of insulin in the residing US market has enabled the North America to garner a considerable portion of the overall market. Furthermore, the existence of an advanced healthcare system leading to expanded patient access to diagnosis and treatment promises lucrative opportunities to the region.

On the other hand, Europe and Asia-Pacific also promise significant growth in the coming years, given the rising penetration of key regional players and the higher development of diabetes in the geriatric population. For instance, in September 2021, Sanofi began supplying its next-generation basal insulin Toujeo Solostar to the European Union countries.

Global Human Insulin Market Recent Developments 

  • In December 2022, Novo Nordisk A/S and Amalgam Rx announced their partnership for the commercialization of Dose Check, a digital insulin initiation and titration app by Amalgam Rx to help people with type 2 diabetes.
  • In December 2022, Eli Lilly and Company announced a collaboration with Eva Pharma to deliver a sustainable supply of affordable human and analog insulin to one million people living with type 1 and type 2 diabetes in low to middle-income countries (LMICs).

Gain a Competitive Edge with Our Global Human Insulin Market Report

  1. Global Human Insulin Market report provides a detailed and thorough analysis of market size, growth rate, competitive landscape, and key players. This comprehensive analysis helps businesses gain a holistic understanding of the market dynamics and make informed decisions.
  2. This report also highlights current market trends and future projections, allowing businesses to identify emerging opportunities and potential challenges. By understanding market forecasts, companies can align their strategies and stay ahead of the competition.
  3. Global Human Insulin Market report aids in assessing and mitigating risks associated with entering or operating in the market.
  4. The report would help in understanding market dynamics, regulatory frameworks, and potential challenges, businesses can develop strategies to minimize risks and optimize their operations

Frequently Asked Questions

   A. The Human Insulin Market is projected to grow at a CAGR of around 5.4% during 2023-28.

   A. The surging prevalence of diabetes and increased product launches are expected to drive the market during 2023-28.

   A. B.Braun (B. Braum Melsungen), Becton, Dickinson and Company (BD), Biocon Limited, Biodel Inc., Eli Lilly and Company, Julphar (Gulf Pharmaceutical Industry), Novo Nordisk A/S, Sanofi, Wockhardt Ltd., and The Ypsomed Group are the top players in the market.

   A. Insulin Analogs & Biosimilars are anticipated to emerge as an area of remunerative opportunities for the leading players in the market during the forecast period.

   A. Globally, North America would provide lucrative prospects for the Human Insulin Market in the years ahead.

   A. The consumers' shift to Insulin Analogs is the key trend shaping the market growth during 2023-28.

   A. Rising research and development in the treatment and prevention of diabetes are the growth opportunities driving the market through 2028.

   A. Inadequate health reimbursement and lower diagnosis rate in emerging countries are the possible restraints affecting the growth of the market.

Global Human Insulin Market Research Report (2023-2028) - Table of Contents

 

  1. Market Segmentation
  2. Introduction
    1. Product Definition
    2. Research Process
    3. Assumptions
  3. Executive Summary
  4. Global Human Insulin Market Porters Five Forces Analysis
  5. Global Human Insulin Market Trends & Insights
  6. Global Human Insulin Market Dynamics
    1. Drivers
    2. Challenges
  7. Global Human Insulin Market Growth Opportunities & Hotspots
  8. Global Human Insulin Market Policy & Regulations
  9. Global Human Insulin Market Analysis, 2018-2028F
    1. Market Size & Outlook
      1. Revenues (USD Million)
    2. Market Share & Outlook
      1. By Product Type
        1. Human Insulin Drugs
          1. Insulin Analogs & Biosimilars
            1. Long Acting Biosimilars
            2. Rapid Acting Biosimilars
            3. Premixed Biosimilars
          2. Human Insulin Biologics
            1. Short Acting Biologics
            2. Intermediate Acting Biologics
            3. Premixed Biologics
        2. Human Insulin Delivery Devices
          1. Syringes
          2. Pens
            1. Disposable Pens
            2. Reusable Pens
          3. Pen Needles
            1. Standard Pen Needles
            2. Safety Pen Needles
      2. By Application
        1. Type I Diabetes
        2. Type II Diabetes
      3. By Region
        1. North America
        2. South America
        3. Europe
        4. The Middle East & Africa
        5. Asia-Pacific
      4. By Company
        1. Market Share
        2. Competition Characteristics
  10. North America Human Insulin Market Analysis, 2018-2028F
    1. Market Size & Outlook
      1. Revenues (USD Million)
    2. Market Share & Outlook
      1. By Product Type
      2. By Application
      3. By Country
        1. The US
        2. Canada
        3. Mexico
    3. The US Human Insulin Market Analysis, 2018-2028F
      1. Market Size & Outlook
        1. Revenues (USD Million)
      2. Market Share & Outlook
        1. By Product Type
        2. By Application
    4. Canada Human Insulin Market Analysis, 2018-2028F
      1. Market Size & Outlook
        1. Revenues (USD Million)
      2. Market Share & Outlook
        1. By Product Type
        2. By Application
    5. Mexico Human Insulin Market Analysis, 2018-2028F
      1. Market Size & Outlook
        1. Revenues (USD Million)
      2. Market Share & Outlook
        1. By Product Type
        2. By Application
  11. South America Human Insulin Market Analysis, 2018-2028F
    1. Market Size & Outlook
      1. Revenues (USD Million)
    2. Market Share & Outlook
      1. By Product Type
      2. By Application
      3. By Country
        1. Brazil
        2. Argentina
        3. Rest of South America
    3. Brazil Human Insulin Market Analysis, 2018-2028F
      1. Market Size & Outlook
        1. Revenues (USD Million)
      2. Market Share & Outlook
        1. By Product Type
        2. By Application
    4. Argentina Human Insulin Market Analysis, 2018-2028F
      1. Market Size & Outlook
        1. Revenues (USD Million)
      2. Market Share & Outlook
        1. By Product Type
        2. By Application
  12. Europe Human Insulin Market Analysis, 2018-2028F
    1. Market Size & Outlook
      1. Revenues (USD Million)
    2. Market Share & Outlook
      1. By Product Type
      2. By Application
      3. By Country
        1. The UK
        2. Germany
        3. Italy
        4. France
        5. Spain
        6. Rest of Europe
    3. The UK Human Insulin Market Analysis, 2018-2028F
      1. Market Size & Outlook
        1. Revenues (USD Million)
      2. Market Share & Outlook
        1. By Product Type
        2. By Application
    4. Germany Human Insulin Market Analysis, 2018-2028F
      1. Market Size & Outlook
        1. Revenues (USD Million)
      2. Market Share & Outlook
        1. By Product Type
        2. By Application
    5. Italy Human Insulin Market Analysis, 2018-2028F
      1. Market Size & Outlook
        1. Revenues (USD Million)
      2. Market Share & Outlook
        1. By Product Type
        2. By Application
    6. France Human Insulin Market Analysis, 2018-2028F
      1. Market Size & Outlook
        1. Revenues (USD Million)
      2. Market Share & Outlook
        1. By Product Type
        2. By Application
    7. Spain Human Insulin Market Analysis, 2018-2028F
      1. Market Size & Outlook
        1. Revenues (USD Million)
      2. Market Share & Outlook
        1. By Product Type
        2. By Application
  13. The Middle East & Africa Human Insulin Market Analysis, 2018-2028F
    1. Market Size & Outlook
      1. Revenues (USD Million)
    2. Market Share & Outlook
      1. By Product Type
      2. By Application
      3. By Country
        1. GCC
        2. South Africa
        3. Rest of the Middle East & Africa
    3. GCC Human Insulin Market Analysis, 2018-2028F
      1. Market Size & Outlook
        1. Revenues (USD Million)
      2. Market Share & Outlook
        1. By Product Type
        2. By Application
    4. South Africa Human Insulin Market Analysis, 2018-2028F
      1. Market Size & Outlook
        1. Revenues (USD Million)
      2. Market Share & Outlook
        1. By Product Type
        2. By Application
  14. Asia-Pacific Human Insulin Market Analysis, 2018-2028F
    1. Market Size & Outlook
      1. Revenues (USD Million)
    2. Market Share & Outlook
      1. By Product Type
      2. By Application
      3. By Country
        1. China
        2. India
        3. Japan
        4. South Korea
        5. Australia
        6. Rest of Asia-Pacific
    3. China Human Insulin Market Analysis, 2018-2028F
      1. Market Size & Outlook
        1. Revenues (USD Million)
      2. Market Share & Outlook
        1. By Product Type
        2. By Application
    4. India Human Insulin Market Analysis, 2018-2028F
      1. Market Size & Outlook
        1. Revenues (USD Million)
      2. Market Share & Outlook
        1. By Product Type
        2. By Application
    5. Japan Human Insulin Market Analysis, 2018-2028F
      1. Market Size & Outlook
        1. Revenues (USD Million)
      2. Market Share & Outlook
        1. By Product Type
        2. By Application
    6. South Korea Human Insulin Market Analysis, 2018-2028F
      1. Market Size & Outlook
        1. Revenues (USD Million)
      2. Market Share & Outlook
        1. By Product Type
        2. By Application
    7. Australia Human Insulin Market Analysis, 2018-2028F
      1. Market Size & Outlook
        1. Revenues (USD Million)
      2. Market Share & Outlook
        1. By Product Type
        2. By Application
  15. Global Human Insulin Market Key Strategic Imperatives for Success & Growth
  16. Competitive Benchmarking
    1. Competition Matrix
      1. Product Portfolio
      2. Target Markets
      3. Target End Users
      4. Research & Development
      5. Strategic Alliances
      6. Strategic Initiatives
    2. Company Profiles (Business Description, Product Offering, Strategic Alliances or Partnerships, etc)
      1. B. Braun (B. Braun Melsungen)
      2. Becton, Dickinson and Company (BD)
      3. Biocon Limited
      4. Biodel Inc.
      5. Eli Lilly and Company
      6. Julphar (Gulf Pharmaceutical Industry)
      7. Novo Nordisk A/S
      8. Sanofi
      9. Wockhardt Ltd.
      10. The Ypsomed Group
      11. Others
  17. Disclaimer


Human Insulin Market - Segmentation Slide